Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- STZ +2.8%, BKE +0.9% (March comps)
Other news:
- ELYM +51.7% (acquires Tenet Medicines and concurrent $120 million private placement)
- ALPN +36.9% (VRTX to acquire ALPN for $65/sh; aslo provides updated clinical data from Povetacicept in IgA Nephropathy)
- LPCN +15.2% (LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity)
- ARVN +6.6% (enters into a transaction with Novartis (NVS), including a global license agreement for the development and commercialization of PROTAC Androgen Receptor Protein Degrader ARV-766 for the treatment of prostate cancer)
- STE +2.5% (to divest its Dental segment to Peak Rock Capital for $787.5 million)
- DNTH +2.5% (Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting)
- ARTNA +2% (says it's prepared to meet EPA's new drinking water standard)
- CWT +2% (says it's well positioned to meet EPA's new drinking water standard)
- SHO +1.8% (to acquire Hyatt Regency San Antonio Riverwalk for $230 mln)
- ORC +1.5% (announces estimated first quarter 2024 results, april 2024 monthly dividend and March 31, 2024 RMBS portfolio characteristics)
- AZN +1.3% (raises annual dividend by 7% to $3.10 per share)
- HRZN +1.3% (provides first quarter 2024 portfolio update)